Elegen Early Access Partners Receive High-Complexity, Long DNA Sequences in Rapid Time

DNA lengths of 15,000 base pairs and higher represent twice the length of the Company’s recently launched flagship product, ENFINIA DNA, and industry-leading complexity and turnaround time

New early access program announced to gather customer requirements and accelerate workflows across pharma, agriculture, and chemical industries

Elegen, a leader in DNA innovation, today announced the expedited delivery of high-complexity DNA sequences longer than 15,000 base pairs to members of their exclusive early access program. The deliveries demonstrate Elegen’s commitment to continuously enhancing its DNA offering and empowering its customers to realize the full potential of synthetic biology.

Elegen’s early access partners can order DNA up to at least 15,000 base pairs long delivered in a plasmid and very complex sequences not readily accepted by other suppliers, including plasmid replication origins, promoters, inverted terminal repeats, and long terminal repeats. For the new program, Elegen has expanded its synthesis acceptance criteria for repeat regions from 30 to 200 base pairs and hairpins from 25 to 60 base pairs. The company has also expanded the range of guanine-cytosine content accepted by 16%, going from a range of 16% - 80% to 8% - 88%.

Access to longer double-stranded DNA enables Elegen’s early access partners to further reduce the cost and effort of producing long, multi-gene constructs without compromising the delivery time or DNA quality. Alec Nielsen, Co-founder and CEO of Asimov, an existing early access partner, said, “We are extremely impressed with Elegen’s ability to produce DNA quickly, including difficult sequences. They have produced multiple difficult sequences for us which we could not get from other sources as a single fragment.” Further adding, “In addition to a great success rate on their standard rapid turn product, they also produced several extremely difficult sequences with their new technology, including a construct containing a GS linker with an embedded repeat more than 50 bases long and another construct containing a region with >90% GC. We are definitely looking forward to working with them more in the future.”

Elegen launched their first product, ENFINIA™ DNA, in March, delivering customers NGS-verified DNA up to 7,000 base pairs long in 7 business days with error rates as low as 1:70,000 base pairs. Shipments to members of the program already demonstrate a greater than two-fold leap in DNA length and advancements in manufacturing historically challenging, high-complexity sequences. Elegen’s new early access program intends to capture customer feedback to accelerate workflows across all industries relying on synthetic DNA, innovate its DNA products, and catalyze their adoption.

“We have seen a tremendous response from the market and believe our products are solving problems that have plagued the synthetic biology industry for years,” said Matt Hill, Elegen Founder and CEO. “I truly believe that delivering longer, more complex DNA faster will accelerate innovation across industries and bring about the bio-revolution promised by synthetic biology.”

Learn more about Elegen’s early access program by visiting www.elegenbio.com/company/partnering

Elegen is sponsoring and participating in a panel on the “Evolution of DNA Supply: What Advances in DNA Synthesis will Unlock the Agile Development of Biology” at the SynBioBeta conference taking place from May 23-25 in Oakland, Calif. Visit www.synbiobeta.com for more information and stop by booth #28 to visit the Elegen team and learn how rapid, long, accurate DNA can streamline your company’s workflows to save costs and time.

About Elegen

Elegen is bringing unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in the life sciences. The company is led by seasoned leaders with decades of experience developing novel and scalable approaches in molecular biology, chemistry, and microfluidics. Elegen uses a proprietary microfluidics approach to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare, and pharma industries. Founded in 2017, Elegen is privately held and based in the San Francisco Bay Area. For more information, visit elegenbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005454/en/

“We have seen a tremendous response from the market and believe our products are solving problems that have plagued the synthetic biology industry for years,” said Matt Hill, Elegen Founder and CEO.